Search

Your search keyword '"Hu, Shu-Ching"' showing total 4 results
Start Over Author "Hu, Shu-Ching" Journal journal of parkinson's disease
4 results on '"Hu, Shu-Ching"'

1. Hallucinations and Development of Dementia in Parkinson's Disease.

Author

Gryc, Wojciech, Roberts, Kathryn A, Zabetian, Cyrus P, Weintraub, Daniel, Trojanowski, John Q, Quinn, Joseph F, Hiller, Amie L, Chung, Kathryn A, Poston, Kathleen L, Yang, Laurice, Hu, Shu-Ching, Edwards, Karen L, Montine, Thomas J, and Cholerton, Brenna A

Subjects
Biomedical and Clinical Sciences, Neurosciences, Dementia, Brain Disorders, Aging, Mental Health, Clinical Trials and Supportive Activities, Acquired Cognitive Impairment, Clinical Research, Neurodegenerative, Parkinson's Disease, Neurological, Aged, Behavioral Symptoms, Cognitive Dysfunction, Cross-Sectional Studies, Female, Hallucinations, Humans, Longitudinal Studies, Male, Middle Aged, Parkinson Disease, Behavioral symptoms, cognition, dementia, hallucinations, Parkinson's disease, Parkinson’s disease, Biochemistry and Cell Biology
Abstract

Neuropsychiatric symptoms are common in Parkinson's disease (PD). We investigated the relationship between neuropsychiatric symptoms and current and future diagnosis of PD dementia (PDD). Individuals with PD who had a study partner were enrolled (n = 696). Study partners were administered the Neuropsychiatric Inventory or Neuropsychiatric Inventory Questionnaire at baseline. Participants were assigned a cognitive diagnosis at baseline and follow up visits. Hallucinations were significantly associated with a diagnosis of PDD cross-sectionally (p

Published
2020

2. Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson’s Disease

Author

Hossein-nezhad, Arash, Fatemi, Roya Pedram, Ahmad, Rili, Peskind, Elaine R., Zabetian, Cyrus P., Hu, Shu-Ching, Shi, Min, Wahlestedt, Claes, Zhang, Jing, and Faghihi, Mohammad Ali

Subjects
Research Report, Male, Gene Expression Profiling, biomarkers, High-Throughput Nucleotide Sequencing, RNA sequencing, Parkinson Disease, Middle Aged, Real-Time Polymerase Chain Reaction, cerebrospinal fluid, Humans, RNA, Female, long noncoding RNA, Transcriptome, Aged
Abstract

Background: Parkinson’s disease (PD) is a debilitating neurological disorder for which prognostic and diagnostic biomarkers are lacking. Cerebrospinal fluid (CSF) is an accessible body fluid that comes into direct contact with the central nervous system (CNS) and acts as a nuclease-free repository where RNA transcripts shed by brain tissues can reside for extended periods of time. Objective: We studied the RNA species present in the CSF of PD patients to identify novel diagnostic biomarkers. Methods: Small volumes of CSF from 27 PD patients and 30 healthy age- and sex-matched controls were used for RNA extraction followed by next-generation sequencing (RNA-seq) using the Illumina platform. CSF contains a number of fragmented RNA species that were individually sequenced and analyzed. Comparing PD to control subjects, we observed a pool of dysregulated sequencing tags that were further analyzed and validated by quantitative real-time PCR (qRT-PCR). Results: A total of 201 differentially expressed sequencing tags (DETs), including 92 up-regulated and 109 down-regulated DETs were identified. We validated the following DETs by real time PCR in the patient samples: Dnmt1, Ezh2, CCR3, SSTR5,PTPRC, UBC, NDUFV2, BMP7, SCN9, SCN9 antisense (AC010127.3), and long noncoding RNAs AC079630 and UC001lva.4 (close to the LRRK2 gene locus), as potential PD biomarkers. Conclusions: The CSF is a unique environment that contains many species of RNA. Our work demonstrates that CSF can potentially be used to identify biomarkers for the detection and tracking of disease progression and evaluation of therapeutic outcomes.

Published
2016

3. Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics

Author

Cholerton, Brenna A., primary, Zabetian, Cyrus P., additional, Quinn, Joseph F., additional, Chung, Kathryn A., additional, Peterson, Amie, additional, Espay, Alberto J., additional, Revilla, Fredy J., additional, Devoto, Johnna, additional, Watson, G. Stennis, additional, Hu, Shu-Ching, additional, Edwards, Karen L., additional, Montine, Thomas J., additional, and Leverenz, James B., additional

Published
2013
Full Text
View/download PDF

4. Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics

Author

Espay, Alberto J., Revilla, Fredy J., Devoto, Johnna, Watson, G. Stennis, Hu, Shu-Ching, Edwards, Karen L., and Montine, Thomas J.

Abstract

Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results